Service Line:+1-315-239-3085
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:[email protected]
Catalog Number | YR1200 |
---|---|
Product Name | Anti-Human HGF Recombinant Antibody(Rilotumumab) |
Molecular Name | Rilotumumab |
Alias | Anti-HGF Recombinant Antibody, Research Grade Rilotumumab |
CAS Number | 872514-65-3 |
Target | HGF[Homo sapiens] |
Isotype | IgG2 Kappa |
Clonity | Monoclonal |
Source | CHO Cells |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Purity | >95% as determined by SDS-PAGE |
Buffer | PBS, pH7.5 |
Background | Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy. |
Storage | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |